Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
8 evidence topics · 8 sources
HPV testing of oropharyngeal carcinoma by p16 immunohistochemistry
“Recommendation 2. For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC. In certain scenarios HPV-specific testing should be performed: (1) in geographic regions with a low prevalence of HR-HPV–associated OPSCC; (2) when p16 IHC is equivocal (50%–70% staining or when staining is extensive but weak); (3) when there is a discrepancy between p16 IHC and morphology; (4) for large, multisite tumors overlapping the oropharynx; (5) when specimens are from a non-tonsillar, non–base of tongue oropharyngeal site; and (6) when required by clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For an OPSCC with classic characteristics, p16 IHC remains the optimal option for HR-HPV testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No routine HPV testing of oral cavity, laryngeal, and hypopharyngeal carcinoma
“Recommendation 8. Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV-specific test methods
“Recommendation 12. For HPV-specific testing, pathologists should use tests that exhibit optimal performance characteristics—such as RNA-ISH or DNA PCR—and have adequate coverage of non–HPV 16 high-risk types. DNA-ISH is not recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved PD-L1 companion diagnostic for pembrolizumab in HNSCC
| Field | Quoted entry |
|---|---|
| Diagnostic name | “PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)” |
| Indication and specimen | “Head and Neck Squamous Cell Carcinoma (HNSCC) - Tissue” |
| Drug | “Keytruda (pembrolizumab) BLA 125514” |
| Biomarker | “PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]” |
| Approval | “P150013/S014 (06/10/2019)” |